<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280318</url>
  </required_header>
  <id_info>
    <org_study_id>UCL-ONCO 2008-03</org_study_id>
    <secondary_id>Academic study</secondary_id>
    <nct_id>NCT01280318</nct_id>
  </id_info>
  <brief_title>Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery</brief_title>
  <acronym>HNSCC</acronym>
  <official_title>Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The obvious hypothesis is that the application of peri-operative targeted biological agents
      may counteract the tumor growth effect of these circulating factors and improve patient
      outcome
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>identification of the biomarkers could lead to the development of peri-operative targeted therapies to decrease the risk of local and distant tumor growth</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the results of group I with groups II and III</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Growth Factor</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with operable head and neck squamous cell carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients treated by neck ansd head surgery for a non-oncological disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients treated before surgery with 3 doses of neoadjuvant cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>head and neck surgery</intervention_name>
    <description>Blood Sample of biomakers at 3 days, 5 weeks and 3 months after surgery.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years and over

             _ histological proven squamous cell carcinoma of the oral cavity, oropharynx,
             hypopharinx or larynx

          -  Patients selected for a primary surgical treatment

          -  no distant metastases

          -  no active second malignancy during the last 5 years except non melanoma skin cancer or
             carcinoma in situ of the cervix

          -  no prior or concurrent evidence of uncontrolled severe pathology precluding
             administration of surgery

          -  life expectancy of more than 3 months

          -  not pregnant or nursing; fertile patients both male and female, must use effective
             contraception

          -  absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial

          -  signed informed consent

          -  performance status ECOG 0-1

        Exclusion Criteria:

          -  Nasopharynx cancer

          -  past or current malignancy other than HNSCC

          -  performance ECOG status more than 2

          -  concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not
             indicated in the study protocol

          -  use of any investigational agents within 4 weeks prior to entry

          -  Previous exposure to EGFR targeting therapy

          -  known grade hypersensitivity to cetuximab

          -  legal incapacity or limited legal capacity or medical or psychological condition which
             in the opiniion of the investigator would not permit the patient to complete the study
             or sign meaningful informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pascal Machiels, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires St Luc-UCL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean-Pascal Machiels</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2011</study_first_submitted>
  <study_first_submitted_qc>January 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2011</study_first_posted>
  <last_update_submitted>November 13, 2012</last_update_submitted>
  <last_update_submitted_qc>November 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

